Galapagos NV LKFT
Annual
Quarterly
No annual revenue total was found in GALAPAGOS NV's SEC filings.
Galapagos NV (LKFT) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
65.90M
+0.0% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LKFT (Nasdaq), GLPGF (OTC)
- Incorporated in
- Belgium
- Headquarters
- 2800 Mechelen
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1421876
- Former names
- GALAPAGOS NV (until May 6, 2026)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Cash and investments | $40.0M | $40.3M | $34.5M | $97.3M | $807.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Nov 4, 2026 | Nov 4, 2026 |
| 6-K | Current report (foreign issuer) | Nov 2, 2026 | Nov 2, 2026 |
| 6-K | Current report (foreign issuer) | Oct 20, 2026 | Oct 20, 2026 |
| 6-K | Current report (foreign issuer) | Oct 15, 2026 | Oct 14, 2026 |
| 6-K | Current report (foreign issuer) | Oct 13, 2026 | Oct 13, 2026 |
| 6-K | Current report (foreign issuer) | Oct 9, 2026 | Oct 8, 2026 |
All 545 Galapagos NV SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.